These images showcase the remarkable healing potential of our technology—compelling the founders of New Day Pharmaceuticals to make their initial investment in bringing this breakthrough to market.
While we see an incredible financial opportunity in this innovation, our greatest motivation is the chance to change lives by providing real relief to those suffering from plaque psoriasis and other debilitating skin conditions.
Together, we are advancing science, innovation, and hope
Our IDB01 technology platform is a versatile and powerful innovation with demonstrated effectiveness in treating burns, wounds, bedsores, and plaque psoriasis. More than just a single product, IDB01 represents a breakthrough in botanical-based therapies, offering broad potential across multiple therapeutic areas.
While our first target is plaque psoriasis, we are actively exploring additional applications to expand this game-changing technology into new areas of dermatology and wound care.
Harnessing the power of nature to drive real medical advancements.
At New Day Pharmaceuticals, we bridge the gap between the power of nature and the rigor of pharmaceutical science. Our expert team, led by seasoned industry professionals, is dedicated to developing naturally derived, clinically proven therapies that address major health challenges.
We take a unique, two-pronged approach to product development, ensuring that groundbreaking natural therapies reach the market quickly and efficiently.
1. Over-the-Counter (OTC) Products – We introduce our formulations as cosmeceuticals or dietary supplements, allowing consumers to access high-quality, clinically backed natural solutions while we advance regulatory approval.
2. Pharmaceutical Development – In parallel, we pursue botanical drug approval through rigorous clinical research, bringing validated, physician-recommended treatments into mainstream medicine.
This strategy enables us to generate immediate market traction while advancing the long-term goal of regulatory-approved pharmaceutical solutions.
Our first product is a natural extract that has demonstrated remarkable healing benefits in patients with severe plaque psoriasis. As part of our dual-market strategy, we are introducing DermalGuard™—our first cosmeceutical solution—while simultaneously developing a new, pharmaceutical-grade formulation through the botanical drug approval process.
This approach allows us to bring effective, naturally derived therapies to market quickly, while also pursuing regulatory approval for a clinically validated prescription treatment.
The Founders of New Day Pharmaceuticals have provided the pre-seed funding to launch our mission of bringing naturally derived, clinically validated therapies to market.
We are now offering a limited opportunity for Accredited Investors to join us as we bring our first product, DermalGuard™—a groundbreaking natural treatment for plaque psoriasis—to market in 2025.
This is your chance to be part of an innovative healthcare venture with high growth potential in both the cosmeceutical and pharmaceutical markets.
Click here to learn more about this exclusive investment opportunity.
SPECIAL OFFER FOR FIRST $100,000 OF INVESTMENT AVAILABLE